Bioscience Equity Partners

Investors often put money into phase II and phase III trials of novel treatments and medical devices while distancing themselves from funding the preclinical stages. Though primarily due to the high risk involved, it is a setback impeding early-stage medtech and biotech start-ups from continuing their development processes. Without investment, most end up having to stop the research and development of their drug compound or medical device before it reaches the clinical trial stage.

Bioscience Equity Partners is a proven game-changer for these players as the gateway for funds toward credible early-stage developments. Established as a leading investor in early-stage drug or medical device development, from discovery to preclinical, the company takes a scientific approach to investing and finance advising to ultimately benefit patients.

Bioscience Equity Partners strategically dives into a client’s technology and innovation to evaluate an organization for funding instead of following the profit-and-loss valuation method. This helps it anticipate the impact of intellectual property, whether a drug or medical device, on patients and predict how different markets will perceive the product.

Bioscience Equity Partners works with funding partners and clients to build an effective development plan and management team while setting milestones and finalizing budgets. These are crucial elements that steer the corporate vehicle toward success. Once these factors are determined properly, it brings in funds through partners and helps clients achieve an initial public offering (IPO) to take their innovations to market.

“When biotech companies attain IPO during clinical trials, it opens the window for investors to realize capital gains on NASDAQ at any time,” says Lei Xu, Managing Partner, Bioscience Equity Partners.

This encourages many venture capitalists and consortiums of funds to take the risk and invest in the early stages. Investors or venture capitalists don’t need to wait seven to eight years for FDA approval to create value but can exit after a much shorter time of 24 to 36 months once the biotech firm is listed on the exchange, which is a significant value creation event.

“As a cornerstone investor and investment banker, we encourage 100 and more funds to invest confidently in the early stage of the medical device or drug development program,” says George Syrmalis, founder and CEO of Bioscience Equity Partners. It also ensures the entire investment transaction adheres to regulatory requirements with a proper private placement memorandum (PPM) and a prospectus.

Bioscience Equity Partners’ ability to gain funds at the early stage of development brings numerous astonishing innovations to the market. For example, it is currently working on taking a UK-based diagnostics company that promises a lab-on-a-chip technology to the market.

Their cutting-edge technology eliminates the need to send specimens to pathology labs and enables general practices and community nurses to conduct all the diagnostic tests within their facilities and obtain results in a few minutes.

Bioscience Equity Partners is also helping another client develop a 3D-printed organ to enable patients to undergo easy transplantation, reducing the possibility of non-compatibility or organ rejection and very importantly reducing dependencies from organ waiting lists.

Bioscience Equity Partners continues to foster many innovations poised to drive exponential value to patients worldwide. Supporting clients throughout their device or drug development journey with its corporate finance advisory and investment banking services, the firm ensures to turn innovations into reality and contribute to a greater cause.